DUBLIN–(BUSINESS WIRE)–The “Obesity – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Obesity- Pipeline Insight, 2022” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
“Obesity- Pipeline Insight, 2022” report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obesity pipeline landscape is provided which includes the disease overview and Obesity treatment guidelines.
The assessment part of the report embraces, in depth Obesity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Obesity R&D. The therapies under development are focused on novel approaches to treat/improve Obesity.
Obesity Emerging Drugs Chapters
This segment of the Obesity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Obesity Emerging Drugs
Tirzepatide: Eli Lily &Company
Tirzepatide also known as LY3298176, (Dual GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of obesity. The dual agonist has also proven to be efficacious in tackling obesity and cardiovascular risk factors associated with T2D.
Danuglipron: Pfizer
Danuglipron (formerly PF 06882961) is an orally administered, small molecule, glucagon-like peptide 1 receptor (GLP 1R) agonist, being developed by Pfizer. The drug is currently in phase 2 stage of development for the treatment of obesity.
XW003:Sciwind Biosciences
XW003 is a novel, long-lasting glucagon-like peptide-1 (GLP-1) analog developed at Sciwind Biosciences. It has been shown to be safe and well tolerated, and induced dose-dependent weight reductions in early clinical trials. . The drug is currently in phase 2 stage of development for the treatment of obesity.
Noiiglutide: Jiangsu Hansoh Pharmaceutical
Noiiglutide is a glucagon-like peptide-1 (GLP-1) analogue being developed by Jiangsu Hansoh Pharmaceutical for the treatment of obesity. Currently, it is in phase 2 stage of development.
MEDI 0382: MedImmune
MEDI0382 is an oxyntomodulin-like peptide with targeted GLP-1 and glucagon receptor activity. MEDI0382 was discovered and developed in MedImmune’s labs and is a dual agonist using natural amino acids. Currently, it is in phase 2 stage of development for the treatment of obesity.
Obesity: Therapeutic Assessment
This segment of the report provides insights about the different Obesity drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Obesity
There are approx. 120+ key companies which are developing the therapies for Obesity. The companies which have their Obesity drug candidates in the most advanced stage, i.e. Phase III include, Eli Lily &Company.
Key Questions Answered
- How many companies are developing Obesity drugs?
- How many Obesity drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obesity?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Obesity therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Obesity and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Novartis
- Eli Lily &Company
- Scohia Pharma
- ERX Pharmaceuticals
- Amgen
- Allysta Pharmaceuticals
- Empros Pharma
- Innovent Biologics
- Boehringer Ingelheim
- Pfizer
Key Products
- ERX1000
- LY3502970
- ARD101
- NN9215
- SCO094
- XW017
- Noiiglutide
Key Topics Covered:
Introduction
Executive Summary
Obesity: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Obesity- Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Tirzepatide: Eli Lily &Company
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Danuglipron: Pfizer
- Product Description
- Research and Development
- Product Development Activities
Initial Stage Products (Phase I)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Drug name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Obesity Key Companies
Obesity Key Products
Obesity- Unmet Needs
Obesity- Market Drivers and Barriers
Obesity- Future Perspectives and Conclusion
Obesity Analyst Views
Obesity Key Companies
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/u9oi21
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900